Published in

Journal of Rheumatology, The Journal of Rheumatology, 9(46), p. 1168-1172, 2019

DOI: 10.3899/jrheum.181185

Links

Tools

Export citation

Search in Google Scholar

Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion

Journal article published in 2019 by Kathleen M. Andersen ORCID, Ayano Kelly ORCID, Anne Lyddiatt ORCID, Clifton O. Bingham ORCID, Vivian P. Bykerk ORCID, Adena Batterman, Joan Westreich, Michelle K. Jones, Marita Cross, Peter M. Brooks ORCID, Lyn March ORCID, Beverley Shea ORCID, Peter Tugwell ORCID, Lee S. Simon ORCID, Robin Christensen ORCID and other authors.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Objective.The Outcome Measures in Rheumatology (OMERACT) Safety Working Group is identifying core safety domains that matter most to patients with rheumatic disease.Methods.International focus groups were held with 39 patients with inflammatory arthritis to identify disease-modifying antirheumatic drug (DMARD) experiences and concerns. Themes were identified by pragmatic thematic coding and discussed in small groups by meeting attendees.Results.Patients view DMARD side effects as a continuum and consider the cumulative effect on day-to-day function. Disease and drug experiences, personal factors, and life circumstances influence tolerance of side effects and treatment persistence.Conclusion.Patients weigh overall adverse effects and benefits over time in relation to experiences and life circumstances.